查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197710

神經診斷市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Neurodiagnostics Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

神經診斷市場預計在預測期內 (2023-2028) 的複合年增長率為 7.5%。

由於世界各國政府實施的封鎖限制，COVID-19 大流行的出現減少了對醫院和診斷中心的訪問，減少了包括全球診斷和治療在內的所有程序。影響了神經診斷市場。 此外，許多研究報告了 COVID-19 對神經系統疾病患者的不良影響，這也有望影響研究市場。 例如，根據國家生物技術信息中心 2021 年 7 月發表的一篇論文，“阿爾茨海默氏病和帕金森氏病預測不同的 COVID-19 結果。”英國生物銀行的一項研究證實，患有癡呆症的人死於 COVID 的風險最高-19.因此，在 COVID-19 大流行期間延遲診斷這些疾病但是，隨著服務和程序的恢復以及診斷中心的開放，神經診斷市場將在預測期內充分發揮其潛力。期待得到它回來。

神經系統疾病患病率上升、老年人口不斷增加、神經診斷學技術進步以及對疾病早期診斷意識的提高是神經診斷學市場的主要驅動力。

阿爾茨海默病、肌萎縮性側索硬化症、亨廷頓舞蹈病、帕金森病和脊髓性肌萎縮症等神經系統疾病患病率的上升是預測期內推動神經診斷市場需求的一個重要因素。 例如，根據世界衛生組織 2021 年 9 月的報告，全球約有 5500 萬人患有癡呆症，每年報告的病例近 1000 萬例。 同樣，根據 2021 年 11 月國家生物技術信息中心一份題為“亨廷頓舞蹈病的流行”的報告，亨廷頓舞蹈病的患病率約為每 10 萬人 10 例，在北美、西北歐、中東和澳大利亞都有發現. 高流行率在 在這些地區，估計每 100,000 人中有 5.96 到 13.70 人。 另一方面，在亞洲，患病率估計為每 100,000 人 0.41-0.70。

隨著神經系統疾病在世界範圍內日益流行，政府和非政府組織正在大力投資開發診斷和治療方法，並為各種神經系統疾病和意識計劃提供資金，這可能會促進市場增長。 例如，2021 年 1 月，Life Science Partners (LSP) 啟動了 1.5 億歐元的“LSP 癡呆症基金”，致力於抗擊神經退行性疾□□病。 該基金將專注於癡呆症藥物和醫療技術開發的所有階段，以治療患者的神經系統疾病。

但是，診斷和成像系統的高成本可能會阻礙市場增長。

神經診斷市場趨勢

診斷和成像系統領域預計將佔據主要市場份額

推動診斷和成像領域發展的主要因素包括神經系統疾病患病率上升、醫學成像中先進技術的日益普及以及人口老齡化。

人口中神經系統疾病負擔的增加增加了對神經診斷設備的需求，進一步推動了預測期內的市場增長。 例如，根據印度公共衛生基金會 2021 年 7 月發表的論文《印度神經系統疾病的負擔》，隨著人口老齡化，印度非傳染性神經系統疾病的患病率正在增加。 中風、頭痛問題和癲癇也是印度神經系統疾病的主要原因。 據同一消息來源稱，2019 年中風導致 699,000 人死亡，佔印度所有死亡人數的 7.4%。

正在開發新的治療和診斷模型，以提供準確的結果，幫助及早發現疾病，並降低多種疾病的治療成本。 隨著可支配收入的增加，人們越來越有能力獲得診斷成像以早期發現疾病。

此外，越來越多的公司專注於開發創新成像產品以實現更好的早期檢測，這也促進了市場增長。 例如，2021 年 11 月，飛利浦在芝加哥舉行的北美放射學會 (RSNA) 年會上推出了其新的人工智能驅動的磁共振產品組合。 同樣，2021 年 3 月，日立醫療系統公司在 2021 年歐洲放射學會開幕式上宣布了兩款配備工作流解決方案“SynergyDrive”的新型永久開放式 MRI 系統。 2020 年 8 月，GE Healthcare 宣布了三項新技術 SIGNA 7.0T 和 SIGNA UHP 3.0，以實現神經學研究並加速臨床應用，以促進我們對阿爾茨海默病和創傷性腦損傷的認識。T，MAGNUS 宣布。

因此，神經系統疾病的日益流行以及對開發先進診斷和成像系統的關注有望推動市場增長。

北美將佔據很大的市場份額，預計在預測期內也會如此

北美受到神經系統疾病患病率上升、人口老齡化、強大的醫療基礎設施、高昂的醫療保健成本以及該地區越來越多的主要市場參與者不斷發展和推出先進診斷設備的困擾. 由於其存在等原因，預計將在全球神經診斷市場佔有較大的市場份額。

神經系統疾病患病率上升是推動該地區市場增長的關鍵因素。 例如，2021年6月，加拿大阿爾茨海默氏症協會首席科學官在接受采訪時表示，“未來10年，加拿大預計將有超過100萬人患上癡呆症。” 這表明北美地區阿爾茨海默氏病患病率的增加預計將增加對診斷和成像系統的需求，這可能會在預測期內進一步推動市場增長。 同樣，根據帕金森基金會公佈的數據，2021 年和 2020 年美國估計有 930 萬帕金森病患者，預計到 2030 年這一數字將上升到 120 萬。

此外，該地區不斷增長的老年人口很可能會增加阿爾茨海默病和帕金森病等與年齡相關的神經退行性疾□□病的易感性，加重神經系統疾病的負擔。 例如，根據阿爾茨海默氏症協會 2021 年 3 月的一份報告，美國約有 620 萬 65 歲以上的人患有阿爾茨海默氏症相關癡呆症，預計到 2060 年這一數字將上升至 1380 萬。

此外，該地區越來越多的診斷產品推出也將有助於預測期內的市場增長。 例如，2021 年 12 月，Fujifilm Healthcare Americas Corporation 在芝加哥舉行的北美放射學會 (RSNA) 上宣布了先進的高場開放式 MRI 系統“Velocity MRI System”。

因此，預計在預測期內，老年人口的增加、神經系統疾病負擔的增加以及產品發布的增加將推動市場擴張。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 神經系統疾病的發病率增加
    • 新診斷技術的採用範圍擴大
  • 市場製約因素
    • 診斷成本高
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按產品類型
    • 臨床測試設備
    • 診斷/成像系統
    • 試劑和耗材
  • 最終用戶
    • 醫院和診所
    • 診斷研究所/診斷影像中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Canon Medical Systems Corporation
    • Siemens Healthineers
    • Koninklijke Philips N.V.
    • Thermo Fisher Scientific, Inc
    • Fujifilm Corporation
    • Natus Medical Incorporated
    • Lifelines Neuro Company
    • Advanced Brain Monitoring, Inc
    • Nihon Kohden Corporation
    • Hoffmann-La Roche Ltd
    • GE Healthcare
    • Mitsar Co. LTD

第7章 市場機會與今後動向

簡介目錄
Product Code: 68292

The Neurodiagnostics Market is expected to register a CAGR of 7.5% during the forecast period (2023 - 2028).

The emergence of the COVID-19 pandemic had its impact on the neurodiagnostic market as all the procedures, including diagnostic and therapeutic around the world were impacted due to the decline in visits to hospitals and diagnostic centers because of lockdown restrictions imposed by various governments globally. Further, many studies reported the negative impact of COVID-19 on patients with neurological disorders, which is also expected to impact the studied market. For instance, according to an article published by the National Center for Biotechnology Information, in July 2021, titled "Alzheimer's and Parkinson's diseases predict different COVID-19 outcomes: A UK Biobank study", it was observed that the patients with dementia have the highest mortality risk from COVID-19. Thus, the delay in the diagnosis of such diseases during the COVID-19 pandemic has further increased the risk for the patients and negatively impacted the market growth. However, with the resumed services and procedures, and the opening of the diagnostic centers, the neurodiagnostic market is expected to regain its full potential over the forecast period.

The increasing prevalence of neurological disorders, rise in the geriatric population, technological advancements in neurodiagnostic, and growing awareness regarding early diagnosis of diseases are the key driving factors in the neurodiagnostic market.

The rising prevalence of neurological disorders such as Alzheimer's disease, Amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, and spinal muscular atrophy is the key factor driving the demand for the neurodiagnostic market over the forecast period. For instance, For according to the September 2021 report of the World Health Organization, about 55 million people around the world are living with dementia, and nearly 10 million cases are reported every year. Similarly, as reported in National Center for Biotechnology Information, in November 2021, titled "Prevalence of Huntington's Disease", it has been observed that the prevalence of Huntington's disease is around 10 cases per 100,000 people, with a higher prevalence in North America, North-western Europe, the Middle East, and Australia. In these regions, the estimates range from 5.96 to 13.70 cases per 100,000 people. Whereas in Asia, the prevalence is estimated to be 0.41-0.70 cases per 100,000 people.

With the growing prevalence of neurological diseases around the world, government and non-government entities are investing heavily in the development of diagnostics and therapeutics for the treatment, as well as increasing funding and awareness programs for various neurological disorders, which may augment the growth of the market. For instance, in January 2021, Life Sciences Partners (LSP) launched the EUR 150 million LSP Dementia Fund, which is dedicated to combating neurodegenerative diseases. This fund will focus on all stages of dementia drugs and Medtech development to treat neurological diseases in patients.

However, the high cost of diagnostic and imaging systems is likely to hinder the growth of the market.

Neurodiagnostics Market Trends

Diagnostic and Imaging Systems Segment is Expected to Hold a Major Market Share

The major factors propelling the growth of the diagnostic and imaging segment include the rising prevalence of neurological disorders, increasing adoption of advanced technologies in medical imaging, and the rising geriatric population.

The increasing burden of neurological disorders among people is increasing the demand for neurodiagnostic devices, which further increases the market growth over the forecast period. For instance, according to a paper published by the Public Health Foundation of India in July 2021, titled " Burden of Neurological disorders in India", the prevalence of non-communicable neurological illnesses is rising in India, owing to the country's aging population. In addition, in India, stroke, headache problems, and epilepsy are the primary causes of neurological illnesses. As per the same source, stroke resulted in the deaths of 699,000 people in 2019, accounting for 7.4% of all deaths in India.

New therapeutic and diagnostic models are being developed that deliver precise results, aid in early disease detection, and reduce the cost of treating various diseases. With the increasing disposable income, people are becoming capable enough to have access to imaging procedures for the early detection of diseases.

Moreover, the increasing company focus on developing innovative imaging and diagnostic products for better and early detection are also contributing to the growth of the market. For instance, in November 2021, Philips launched a new Artificial intelligence-enabled Magnetic Resonance portfolio at the Radiological Society of North America (RSNA) annual meeting in Chicago. Similarly, in March 2021, Hitachi Medical Systems launched two new permanent open MRI systems that are equipped with the SynergyDrive workflow solution at the start of the 2021 European Congress of Radiology. In August 2020, GE Healthcare showcased its three new technologies, SIGNA 7.0T, SIGNA UHP 3.0T, and MAGNUS, to enable neuro research to better understand Alzheimer's disease and traumatic brain injury as well as accelerate clinical translation.

Thus, the increasing prevalence of neurological diseases and the company's focus on developing well-advanced diagnostic and imaging systems are likely to increase the market growth.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global neurodiagnostic market due to the increasing prevalence of neurological disorders, rising geriatric population, presence of robust healthcare infrastructure, high healthcare spending, and presence of major market players continuously evolving and launching advanced diagnostics devices in the region.

The rising prevalence of neurological diseases is the key factor driving the growth of the market in the region. For instance, in June 2021, in an interview, the Chief Science Officer of the Alzheimer Society of Canada stated that "Over the next 10 years, it was anticipated that more than one million people in Canada will be living with dementia." This indicates that the increasing prevalence of Alzheimer's in the North American region is expected to increase the demand for diagnostic and imaging systems, which may further drive the market growth over the forecast period. Similarly, according to the data published by the Parkinson's Foundation, in 2021, an estimated 9,30,000 people were living with Parkinson's disease in the United States 2020, and this number is predicted to increase to 1,2 million by 2030.

Also, the growing geriatric population in the region is expected to increase the burden of neurological disorders, as the geriatric population is more prone to neurodegenerative diseases like Alzheimer's and Parkinson's, age-associated diseases. For instance, according to the March 2021 report of the Alzheimer's Association, approximately 6.2 million people of age 65 years and more are living with Alzheimer's-related dementia in the United States, and it is projected that this number will increase to 13.8 people by 2060.

Moreover, the increasing diagnostic product launches in the region are also contributing to the growth of the market over the forecast period. For instance, In December 2021, Fujifilm Healthcare Americas Corporation presented an advanced high-field open MRI system, Velocity MRI System, at the Radiological Society of North America (RSNA) conference in Chicago.

Hence, the increasing geriatric population, rising burden of neurological disease, and increased product launches are likely to increase the market expansion over the forecast period.

Neurodiagnostics Market Competitor Analysis

The Neurodiagnostics Market is consolidated and consists of several major players operating in specific segments such as imaging and clinical diagnostics etc. In terms of market revenue, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are GE Healthcare, Siemens Healthineers, Philips Healthcare, Thermo Fisher Scientific, Inc, Hitachi, Ltd, Natus Medical Incorporated, Lifelines Neuro Company, Advanced Brain Monitoring, Inc, and Nihon Kohden Corporation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Neurological Diseases
    • 4.2.2 Growing Adoption of Novel Diagnostic Technologies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Diagnosis
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Clinical Testing Instruments
    • 5.1.2 Diagnostic and Imaging Systems
    • 5.1.3 Reagents and Consumables
  • 5.2 By End-User
    • 5.2.1 Hospitals and Clinics
    • 5.2.2 Diagnostic Laboratories and Imaging Centers
    • 5.2.3 Other End-Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Canon Medical Systems Corporation
    • 6.1.2 Siemens Healthineers
    • 6.1.3 Koninklijke Philips N.V.
    • 6.1.4 Thermo Fisher Scientific, Inc
    • 6.1.5 Fujifilm Corporation
    • 6.1.6 Natus Medical Incorporated
    • 6.1.7 Lifelines Neuro Company
    • 6.1.8 Advanced Brain Monitoring, Inc
    • 6.1.9 Nihon Kohden Corporation
    • 6.1.10 Hoffmann-La Roche Ltd
    • 6.1.11 GE Healthcare
    • 6.1.12 Mitsar Co. LTD

7 MARKET OPPORTUNITIES AND FUTURE TRENDS